AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 28433211
Drug: Co-administration of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-administration of ketamine and propofol (CoKP) 0.5 mg/kg each i.v. (with up to three additional doses of 0.25 mg/kg each)
Trial: 28433211
Drug: Ketamine monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine monotherapy (KM)
Trial: 28433211
Drug: Co-administration of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-administration of ketamine and propofol (CoKP)
Trial: 26054140
Drug: Acupuncture and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture and moxibustion at 'Xiasanhuang', once a day, with an interval of 2 days after every 10 treatments for 2 months.
Trial: 26054140
Drug: Benazepril hydrochloride,
RxNorm normalized name: Benazepril Hydrochloride, 5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benazepril hydrochloride, 5 to 10 mg orally, once a day for 2 months.
Trial: 17409109
Drug: Carvedilol at
RxNorm normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carvedilol at a dose of 10-20 mg/day (mean dose: 16 +/- 4 mg/day) for a mean of 12 +/- 1 months
Trial: 15747470
Drug: Cefotiam hexetil
RxNorm normalized name: Cefotiam hexetil hydrochloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefotiam hexetil 200 mg bid over a 5 day period followed by 5 days of placebo
Trial: 15747470
Drug: Cefotiam hexetil
RxNorm normalized name: Cefotiam hexetil hydrochloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefotiam hexetil 200 mg bid over a 10 day period
Trial: 8322791
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose OKT3 (5 mg)
Trial: 7993573
Drug: Low-dose OKT3
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose OKT3 (2 mg)
Trial: 3521443
Drug: Hydrochlorothiazide plus
RxNorm normalized name: hydralazine hydrochloride / hydrochlorothiazide Oral Capsule [Hydralazine Plus]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide plus amiloride (25 mg hydrochlorothiazide + 2.5 mg amiloride)
Trial: 6689277
Drug: Hydrochlorothiazide alone
RxNorm normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide alone (25 mg)
Trial: 10532693
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose warfarin
Trial: 10440141
Drug: Sotalol (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sotalol (40 patients; mean dose = 190 +/- 43 mg/day)
Trial: 10440141
Drug: Placebo (45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (45 patients; mean dose = 176 +/- 32 mg/day)
Trial: 1599636
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg felodipine plus 5 mg enalapril
Trial: 23982575
Drug: Pelvic floor
RxNorm normalized name: Tenscare Kegel Toner Pelvic Floor Trainer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pelvic floor physical therapy (PFPT)
Trial: 31039482
Drug: Aripiprazole augmentation
RxNorm normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Aripiprazole augmentation for 12 weeks
Trial: 30378274
Drug: 4 mL
RxNorm normalized name: ethanol 1.4 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mL of hyperosmolar rectal lubricant daily for 7 days
Trial: 30378274
Drug: Daily oral
RxNorm normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily oral TDF/FTC for 7 days
Trial: 30378274
Drug: Both hyperosmolar
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both hyperosmolar lubricant and daily oral TDF/FTC for 7 days
Trial: 26300329
Drug: Narrative Cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Narrative Cognitive Therapy (NCT)
Trial: 20301014
Drug: Policosanols (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Policosanols (1 to 20 mg/day)
Trial: 16634903
Drug: Methyl aminolaevulinate-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methyl aminolaevulinate-based photodynamic therapy (MAL-PDT), 2 treatments, 2 weeks apart
Trial: 16634903
Drug: Methyl aminolaevulinate-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methyl aminolaevulinate-based photodynamic therapy (MAL-PDT)
Trial: 11037786
Drug: CGP 56697
RxNorm normalized name: Leucoflex CGP KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CGP 56697 (co-artemether) - 4 x 4 tablets over 48 hours
Trial: 11037786
Drug: Chloroquine -
RxNorm normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chloroquine - 4 tablets initially, followed by two tablets each at 6-8, 24, and 48 hours
Trial: 7543434
Drug: Screening with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Screening with alpha‐fetoprotein > or = 20 micrograms/L
Trial: 7543434
Drug: Serum alpha‐fetoprotein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum alpha‐fetoprotein > 20 micrograms/L
Trial: 626810
Drug: Ioglycamide infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ioglycamide infusion at a rate of 4 mg per kg per min for one hour
Trial: 626810
Drug: Ioglycamide infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ioglycamide infusion
Trial: 31294137
Drug: KBMSI-2 (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KBMSI-2 (6 g twice per day for 8 weeks)
Trial: 26562602
Drug: End-of-treatment outcomes
RxNorm normalized name: End-Zit
DrugBank: Octasulfur (DB09353)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: End-of-treatment outcomes (abstinence and good clinical outcome during treatment)
Trial: 26562602
Drug: Logistic regression
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Logistic regression analyses based on good clinical outcome, level of drinking during treatment, age at onset of alcohol dependence, and feeling more energetic
Trial: 21469973
Drug: Drospirenone 2
RxNorm normalized name: drospirenone 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drospirenone 2 mg / Estradiol 1 mg (DRSP/E2)
Trial: 16502051
Drug: Lidocaine gel
RxNorm normalized name: LIDOCAINE 4 g in 100 g EXTRACORPOREAL PATCH [Arthcal 4% Lidocaine Gel Patches]
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine gel and povidine iodine lavage
Trial: 12685672
Drug: Control (Conventional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (Conventional medical treatments)
Trial: 10752744
Drug: AT(H) concentrate
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AT(H) concentrate infusions every 8 hours to raise plasma level to 175% in the first 72 hours after injury
Trial: 10752744
Drug: AT(H) concentrate
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AT(H) concentrate infusions
Trial: 9373047
Drug: CO2-enriched water
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CO2-enriched water (1000 mg CO2/kg)
Trial: 29843811
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy alone (placebo)
Trial: 20090776
Drug: Cocoa flavanols
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cocoa flavanols (CF) 1052 mg day(‐1) for 6 weeks
Trial: 20492527
Drug: Ketoconazole cream
RxNorm normalized name: Ketoconazole
DrugBank: Ketoconazole (DB01026)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketoconazole cream 2%
Trial: 16187171
Drug: Methylene blue
RxNorm normalized name: Methylene Blue
DrugBank: Methylene blue (DB09241)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylene blue (3 mg/kg)
Trial: 10229004
Drug: rHuEPO (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rHuEPO (both doses)
Trial: 1906791
Drug: Temafloxacin 600
RxNorm normalized name: temafloxacin 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Temafloxacin 600 mg twice daily for 7 days starting on day 1 of the contraceptive cycle
Trial: 6654698
Drug: 18 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 18 g/d of sodium DL‐3‐hydroxybutyrate
Trial: 24448036
Drug: Weekly practice
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly practice (once/week for four consecutive weeks)
Trial: 22858715
Drug: 3 mg
RxNorm normalized name: boron 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg OTO-104
Trial: 19321493
Drug: Pioglitazone (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone (15 mg, up to 30 mg)
Trial: 15466981
Drug: Combination tests
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination tests of total and percent free PSA
Trial: 15466981
Drug: PSA >
RxNorm normalized name: Prostate-Specific Antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PSA > 4.0 ng/mL
Trial: 11353359
Drug: Single treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single treatment groups (EMLA and Music)
Trial: 9443116
Drug: High-meat group
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-meat group (HMG) - mean meat content of 27 g/day
Trial: 9443116
Drug: Low-meat group
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-meat group (LMG) - mean meat content of 10 g/day
Trial: 29486879
Drug: Propofol TIVA
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol TIVA (15.0 ± 4.7 mg/kg/h)
Trial: 23652951
Drug: HP802‐247 (5M
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HP802‐247 (5M cells/mL) applied weekly
Trial: 23652951
Drug: Bacitracin ointment
RxNorm normalized name: Bacitracin Ointment
DrugBank: Bacitracin (DB00626)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bacitracin ointment applied daily
Trial: 20450412
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg of oral micronized 17β-estradiol daily for 2 years
Trial: 11101175
Drug: Inhaled budesonide
RxNorm normalized name: budesonide Inhalation Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled budesonide at doses ranging from 200 to 1600 microg administered twice daily for 12 to 20 weeks.
Trial: 9299668
Drug: Omeprazole 40
RxNorm normalized name: omeprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 40 mg daily for 10 days
Trial: 8394191
Drug: Oral conjugated
RxNorm normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral conjugated estrogens (0.625 mg/day)
Trial: 10368794
Drug: Transdermal estradiol
RxNorm normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal estradiol (50 micrograms/day)
Trial: 30397984
Drug: Continuous low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Continuous low-dose isotretinoin (20 mg/day)
Trial: 30397984
Drug: Conventional high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional high-dose isotretinoin (0.5 mg/kg/day)
Trial: 31080813
Drug: Isotretinoin treatment
RxNorm normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isotretinoin treatment
Trial: 23013946
Drug: Heparin-coated poliacrylonitrile
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin-coated poliacrylonitrile AN69ST® membrane without systemic anticoagulation
Trial: 23013946
Drug: Heparin-coated poliacrylonitrile
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin-coated poliacrylonitrile AN69ST® membrane
Trial: 16285357
Drug: Docetaxel chemotherapy
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel chemotherapy every three weeks combined with prednisone
Trial: 16285357
Drug: Mitoxantrone plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mitoxantrone plus low-dose prednisone
Trial: 11977645
Drug: Xeloda (capecitabine)
RxNorm normalized name: capecitabine Oral Tablet [Xeloda]
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Xeloda (capecitabine) at a dose of 2,510 mg/m2/d, bid, for two weeks followed by one week rest as one cycle.
Trial: 11977645
Drug: Xeloda (capecitabine)
RxNorm normalized name: capecitabine Oral Tablet [Xeloda]
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Xeloda (capecitabine) in patients who had failed previous chemotherapy with taxanes and/or anthracycline.
Trial: 7878283
Drug: Verapamil (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil (5 to 10 mg)
Trial: 7878283
Drug: Adenosine triphosphate
RxNorm normalized name: Adenosine triphosphate
DrugBank: ATP (DB00171)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adenosine triphosphate (ATP) (5 to 20 mg)
Trial: 2086208
Drug: Fortified cereal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fortified cereal (bovine haemoglobin concentrate, Fe: 14 mg/100 g of powder)
Trial: 2086208
Drug: Fortified cereal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fortified cereal with additional supplementation of 45 mg Fe for 90 days
Trial: 457522
Drug: Sodium nitrate
RxNorm normalized name: Sodium Nitrate
DrugBank: Sodium nitrate (DB15952)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium nitrate (NaNO3) aerosol inhalation
Trial: 457522
Drug: Sodium chloride
RxNorm normalized name: Sodium Chloride
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium chloride (NaCl) aerosol inhalation
Trial: 29063244
Drug: Fingolimod (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fingolimod (0.5 mg daily)
Trial: 29063244
Drug: Interferon beta-1b
RxNorm normalized name: Interferon Beta-1B
DrugBank: Interferon beta-1b (DB00068)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon beta-1b (250 µg every other day)
Trial: 23896477
Drug: GSK2336805 (≥10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2336805 (≥10 mg single dose)
Trial: 23896477
Drug: GSK2336805 (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2336805 (various doses)
Trial: 19151049
Drug: Lidocaine/tetracaine patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine/tetracaine patch (Synera, Rapydan)
Trial: 19151049
Drug: Lidocaine/prilocaine cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine/prilocaine cream (EMLA)
Trial: 12211502
Drug: Periodontal treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Periodontal treatment before 28 weeks of gestation
Trial: 19426177
Drug: Periodontal treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Periodontal treatment after delivery
Trial: 8686815
Drug: Propofol with
RxNorm normalized name: propofol with medium chain triglycerides 10 mg/mL intravenous emulsion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol with low dose fentanyl
Trial: 8686815
Drug: Midazolam with
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Midazolam with high dose fentanyl
Trial: 1753612
Drug: Drug therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug therapy alone (N=24)
Trial: 1753612
Drug: Drug therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug therapy in combination with hyperbaric oxygenation (N=27)
Trial: 1753612
Drug: Drug therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug therapy in combination with hemosorption (N=26)
Trial: 6802557
Drug: Glucose System
RxNorm normalized name: Atlast Blood Glucose System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose System (TPN with intravenous glucose)
Trial: 6802557
Drug: Lipid System
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipid System (TPN with 50% glucose + 50% intravenous fat)
Trial: 29141663
Drug: Radiotherapy dose
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Radiotherapy dose distribution
Trial: 25760874
Drug: Rivaroxaban (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban (20 mg once daily or 15 mg if creatinine clearance was 30-49 ml/min)
Trial: 25760874
Drug: Dose-adjusted Vitamin
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose-adjusted Vitamin K antagonists (VKAs)
Trial: 23432642
Drug: Glycine powder
RxNorm normalized name: Nutricia Glycine Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycine powder air-polishing (GPAP) for 5 sec in addition to oral hygiene instruction and non-surgical debridement.
Trial: 23432642
Drug: Non-surgical debridement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-surgical debridement and oral hygiene instruction (Control group).
Trial: 22989394
Drug: Desmoteplase 90
RxNorm normalized name: Desmoteplase
DrugBank: Desmoteplase (DB04925)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desmoteplase 90 μg/kg IV bolus injection
Trial: 22989394
Drug: Desmoteplase 70
RxNorm normalized name: Desmoteplase
DrugBank: Desmoteplase (DB04925)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desmoteplase 70 and 90 μg/kg IV bolus injection
Trial: 18829988
Drug: Insulin requirements
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin requirements
Trial: 15111683
Drug: Ropinirole (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropinirole (0.5 to 6.0 mg/day)
Trial: 12196868
Drug: Weekly courses
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly courses of betamethasone until 33 weeks' gestation or delivery
Trial: 2692970
Drug: Chewable cimetidine
RxNorm normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chewable cimetidine (200 mg)
Trial: 2692970
Drug: Chewable antacid
RxNorm normalized name: CALCIUM CARBONATE 500 mg ORAL TABLET, CHEWABLE [CALCIUM CARBONATE CHEWABLE ANTACID]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chewable antacid
Trial: 25415290
Drug: Gardasil (HPV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gardasil (HPV vaccine)
Trial: 25415290
Drug: Saline placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline placebo vaccine
Trial: 22815050
Drug: EV-077 0.0125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EV-077 0.0125 mg/kg
Trial: 22815050
Drug: EV-077 0.125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EV-077 0.125 mg/kg
Trial: 22815050
Drug: EV-077 0.375
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EV-077 0.375 mg/kg
Trial: 22815050
Drug: EV-077 0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EV-077 0.75 mg/kg
Trial: 22815050
Drug: EV-077 1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EV-077 1.25 mg/kg
Trial: 22815050
Drug: EV-077 1.875
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EV-077 1.875 mg/kg
Trial: 22815050
Drug: EV-077 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EV-077 2.5 mg/kg
Trial: 22815050
Drug: EV-077 (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EV-077 (all doses)
Trial: 22815050
Drug: EV-077 (plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EV-077 (plasma concentrations above 20 ng/ml)
Trial: 17103040
Drug: Metronidazole (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronidazole (800 mg TID)
Trial: 17103040
Drug: Satranidazole (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Satranidazole (300 mg TID with placebo at mealtime)
Trial: 8267110
Drug: Clozapine with
RxNorm normalized name: Clozapine
DrugBank: Clozapine (DB00363)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clozapine with fluoxetine (N = 6)
Trial: 29275118
Drug: Rituximab maintenance
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab maintenance (500 mg/m2 every 8 weeks for up to 2 years)
Trial: 20810979
Drug: Higher dairy
RxNorm normalized name: Beano Dairy Defense
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher dairy calcium intake (median for tertiles: 156.5, 358.0, and 582.9 mg/d)
Trial: 20810979
Drug: Increased serum
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increased serum 25(OH)D (14.5, 21.2, and 30.2 ng/mL for tertiles)
Trial: 16683415
Drug: Curative radiation
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Curative radiation therapy
Trial: 16683415
Drug: Hypofractionated stereotactic
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypofractionated stereotactic body radiation therapy
Trial: 14688709
Drug: No initial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No initial resection after neoadjuvant therapy for N2 nodal disease
Trial: 12097595
Drug: HPV virus-like
RxNorm normalized name: chikungunya virus antigen, recombinant Senegal strain 37997
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HPV virus-like particle (VLP) vaccine administered intramuscularly at months 0, 2, 6, and a fourth dose at month 12 for half of the participants
Trial: 12097595
Drug: HPV virus-like
RxNorm normalized name: chikungunya virus antigen, recombinant Senegal strain 37997
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HPV virus-like particle (VLP) vaccine